China SXT Pharmaceuticals Net Debt Growth & History (SXTC)
China SXT Pharmaceuticals's net debt was −$27.1M for fiscal 2026.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | −$27.1M | −$9.9M | — |
| 2025 | 2025-03-31 | −$17.1M | −$5.9M | — |
| 2024 | 2024-03-31 | −$11.2M | $5.6M | — |
| 2023 | 2023-03-31 | −$16.8M | −$4.0M | — |
| 2022 | 2022-03-31 | −$12.7M | $570,140 | — |
| 2021 | 2021-03-31 | −$13.3M | −$6.1M | — |
| 2020 | 2020-03-31 | −$7.2M | $2.0M | — |
| 2019 | 2019-03-31 | −$9.2M | — | — |
China SXT Pharmaceuticals quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | −$27.1M | −$9.9M | — |
| Q2 2026 | 2025-09-30 | −$20.0M | −$2.5M | — |
| Q4 2025 | 2025-03-31 | −$17.1M | −$5.9M | — |
| Q2 2025 | 2024-09-30 | −$17.5M | −$6.7M | — |
| Q4 2024 | 2024-03-31 | −$11.2M | $5.6M | — |
| Q2 2024 | 2023-09-30 | −$10.8M | −$9.2M | — |
| Q4 2023 | 2023-03-31 | −$16.8M | −$4.0M | — |
| Q2 2023 | 2022-09-30 | −$1.6M | −$1.6M | — |
| Q4 2022 | 2022-03-31 | −$12.7M | $570,140 | — |
| Q2 2022 | 2021-09-30 | −$7,279 | $10.3M | — |
| Q4 2021 | 2021-03-31 | −$13.3M | −$6.1M | — |
| Q2 2021 | 2020-09-30 | −$10.3M | −$2.9M | — |
| Q4 2020 | 2020-03-31 | −$7.2M | $2.0M | — |
| Q2 2020 | 2019-09-30 | −$7.4M | — | — |
| Q4 2019 | 2019-03-31 | −$9.2M | — | — |
China SXT Pharmaceuticals net debt trends
Over the last five fiscal years, China SXT Pharmaceuticals's net debt decreased from −$13.3M to −$27.1M, a change of −$13.8M. The latest reported quarter, Q4 2026, shows −$27.1M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China SXT Pharmaceuticals source filings ↗